We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+10.41%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$571M
AUM Growth
-$28.1M
Cap. Flow
-$28.6M
Cap. Flow %
-5.01%
Top 10 Hldgs %
76.16%
Holding
50
New
6
Increased
12
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
IMNM icon
Immunome
IMNM
+$9.7M
2
ARVN icon
Arvinas
ARVN
+$8.99M
3
EPIX
ESSA Pharma
EPIX
+$7.04M
4
CRGX
CARGO Therapeutics
CRGX
+$3.78M
5
DNA icon
Ginkgo Bioworks
DNA
+$3.26M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$23M
2
APLT
Applied Therapeutics
APLT
+$11.2M
3
OCUL icon
Ocular Therapeutix
OCUL
+$6.66M
4
CYTK icon
Cytokinetics
CYTK
+$3.98M
5
CPRX
Catalyst Pharmaceutical
CPRX
+$2.24M

Sector Composition

Rank Sector Weight
1 Healthcare 98.12%
2 Miscellaneous 1.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPIX
26
DELISTED
ESSA Pharma
EPIX
$3.96M 0.69%
+2,209,998
New +$7.04M
ABCL icon
27
AbCellera Biologics
ABCL
$4.02B
$2.83M 0.49%
965,000
+165,000
+21% +$459K
URGN icon
28
UroGen Pharma
URGN
$2.22B
$2.34M 0.41%
220,000
-184,100
-46% -$2.2M
RZLT icon
29
Rezolute
RZLT
$480M
$2.28M 0.4%
465,000
-1,563
-0.3% -$7.88K
IMTX icon
30
Immatics
IMTX
$1.28B
$1.17M 0.21%
+165,000
New +$1.42M
IBIO icon
31
iBio
IBIO
$69.5M
$919K 0.16%
375,000
– –
LXEO icon
32
Lexeo Therapeutics
LXEO
$409M
$855K 0.15%
+130,000
New +$1.02M
RGNX icon
33
Regenxbio
RGNX
$619M
$618K 0.11%
+80,000
New +$751K
VTYX
34
DELISTED
Ventyx Biosciences
VTYX
$613K 0.11%
+280,000
New +$635K
PEPG icon
35
PepGen
PEPG
$213M
$417K 0.07%
110,000
-69,200
-39% -$431K
STOK icon
36
Stoke Therapeutics
STOK
$2.1B
$276K 0.05%
+25,000
New +$307K
ADGM
37
Adagio Medical Holdings
ADGM
$11.6M
$116K 0.02%
110,571
– –
ALLK
38
DELISTED
Allakos
ALLK
– –
-2,407,600
Closed -$1.57M
APLT
39
DELISTED
Applied Therapeutics
APLT
– –
-1,320,000
Closed -$11.2M
JBIO
40
Jade Biosciences
JBIO
$1.35B
– –
-12,571
Closed -$920K
CPRX
41
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-112,500
Closed -$2.24M
CYTK icon
42
Cytokinetics
CYTK
$10.8B
– –
-75,300
Closed -$3.98M
KROS icon
43
Keros Therapeutics
KROS
$223M
– –
-395,276
Closed -$23M
LYEL icon
44
Lyell Immunopharma
LYEL
$358M
– –
-69,750
Closed -$1.93M
RGLS
45
DELISTED
Regulus Therapeutics
RGLS
– –
-535,000
Closed -$840K
RLMD icon
46
Relmada Therapeutics
RLMD
$482M
– –
-480,000
Closed -$1.56M
SYRS
47
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-654,943
Closed -$1.41M
RVNC
48
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-275,000
Closed -$1.43M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2024 Portfolio in Review

As of Q4 2024, Opaleye Management held 50 positions worth $571M, down 4.7% from $600M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Opaleye Management withdrew a net $28.6M in Q4 2024, closing 11 positions and reducing 12 holdings. Its most notable exit was Keros Therapeutics, an estimated $23M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in ESSA Pharma worth $3.96M.

  • Opaleye Management's largest Q4 2024 buy was ESSA Pharma: 2,209,998 shares worth $3.96M.
  • Opaleye Management added most to Immunome in Q4 2024, an estimated $9.7M increase.
  • Opaleye Management's biggest Q4 2024 reduction was Ocular Therapeutix, cutting an estimated $6.66M.
  • Opaleye Management fully exited Keros Therapeutics in Q4 2024, selling an estimated $23M.
  • Opaleye Management's ten largest holdings make up 76% of its $571M portfolio in Q4 2024.
  • Opaleye Management opened 6 new positions and closed 11 in Q4 2024.
  • Opaleye Management's portfolio value fell 4.7% quarter-over-quarter to $571M.

Based on Opaleye Management's 13F filing for Q4 2024, filed 14 Feb 2025.